By Blake Brittain

May 29 (Reuters) - Johnson & Johnson's JNJ.N medical device subsidiary Abiomed has won a jury trial in Massachusetts over allegations that it violated Maquet Cardiovascular's patent rights in heart-pump technology.

Abiomed convinced the jury on Thursday that its Impella intravascular heart pumps used to treat heart failure did not infringe a patent related to competing pumps made by Maquet, an Abiomed attorney told Reuters on Friday.

The jury also determined that the patent was invalid, the attorney said.

Maquet is owned by Sweden-based Getinge Group GETIb.ST. Spokespeople and attorneys for the companies did not immediately respond to requests for comment on the verdict on Friday.

Abiomed's first Impella models received U.S. Food and Drug Administration approval in 2008. Johnson & Johnson struck a $16.6 billion all-cash deal in 2022 to buy Abiomed, which specializes in heart pumps, to boost growth in its medical devices unit.

Abiomed products including its flagship Impella pumps earned J&J $1.75 billion in worldwide revenue in 2025, according to a company report. The U.S. Food and Drug Administration has issued several recalls related to Impella models in recent years.

The verdict stems from a lawsuit Maquet filed in 2017. It accused Massachusetts-based Abiomed's Impella pumps of infringing a patent covering a design for a heart pump that can be placed in a specific location within a patient's circulatory system.

The U.S. Court of Appeals for the Federal Circuit revived the case last year after overturning a ruling from the Massachusetts court for Abiomed.

A second, related Maquet patent lawsuit against Abiomed in Massachusetts is still ongoing.

The case is Maquet Cardiovascular LLC v. Abiomed Inc, U.S. District Court for the District of Massachusetts, No. 1:17-cv-12311

For Maquet: Paul Tanck, Christopher McArdle, Neal McLaughlin, Wade Perrin and Andrew Ligotti of Alston & Bird

For Abiomed: John Desmarais, Kerri-Ann Limbeek, Brian Matty and Adam Steinmetz of Desmarais LLP